Cargando…

Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report: Erratum

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708936/ https://www.ncbi.nlm.nih.gov/pubmed/31335739 http://dx.doi.org/10.1097/MD.0000000000016555

Ejemplares similares

Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report
por: Ciurleo, Rosella, et al.
Publicado: (2019)

Erratum to “A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod”
Publicado: (2021)

Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study
por: Renaud, Cédric O., et al.
Publicado: (2022)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”
Publicado: (2020)

Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate
por: Ma, Brandy B., et al.
Publicado: (2016)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
Publicado: (2023)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Erratum: Diagnostic difficulties by the unusual presentations in children and adolescents with Hashimoto thyroiditis
por: Ersoy, Betül, et al.
Publicado: (2016)

Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate
por: Kania, Karolina, et al.
Publicado: (2022)

Erratum to: Chromatin remodeling factor LSH affects fumarate hydratase as a cancer driver
por: Liu, Shuang, et al.
Publicado: (2016)

Erratum to: Promoting Remyelination in Multiple Sclerosis—Recent Advances
por: Münzel, E. Jolanda, et al.
Publicado: (2013)

Endocannabinoid levels in peripheral blood mononuclear cells of multiple sclerosis patients treated with dimethyl fumarate
por: Sánchez-Sanz, Alicia, et al.
Publicado: (2022)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis
por: Guerriero, Claudia, et al.
Publicado: (2022)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

Erratum: The Effects of Bronchiectasis on Asthma Exacerbation
por: Kang, Hye Ran, et al.
Publicado: (2014)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Erratum to “PICK1 Deficiency Exacerbates Sepsis-Associated Acute Kidney Injury”
por: Dou, Qian, et al.
Publicado: (2022)

Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients
por: Sánchez-Sanz, Alicia, et al.
Publicado: (2023)

Erratum to: Objective Biomarkers for Clinical Relapse in Multiple Sclerosis: A Metabolomics Approach
Publicado: (2021)

Erratum: Choroidal Thickness in Multiple Sclerosis: An Optical Coherence Tomography Study
por: Masala, Alessandro, et al.
Publicado: (2022)

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models
por: Kihara, Yasuyuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fc9t2gd7n7t837tijj3kff3va3